This report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of B-cell NHL in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Study Period: 2017-2028
B-cell NHL Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Incidence of NHL, Total Incidence cases of B cell-NHL, Gender-specific Incidence of B-cell NHL, Age-specific Incidence of B-cell NHL, Subtype - Specific Incidence of B-cell NHL and Stage-Specific Incidence of B-cell NHL] scenario of B-cell NHL in the 7MM Countries covering United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2028.
Analysts have assessed that the total prevalent population of B-cell NHL in the 7MM was 141,873 in 2017. In addition to this, there was a gender difference in the disease. It was seen that, the B-cell lymphoma cases occurs more frequently in male population as compared to female. In 2017, a more number of males were affected by the disease, i.e., 55% of the B-cell NHL cases in the 7MM, which is equivalent to 78,030 cases in comparison to the females.
B-cell NHL Drug Chapters
The treatment of B-cell NHL is mainly based on the subtype and stage of the disease, according to the subtype and stage of the disease, initial therapy and intensity of treatment taken into consideration. In general, the goal of treatment is to destroy as many lymphoma cells as possible and to induce complete remission. Treatment can also keep non-Hodgkin lymphoma (NHL) in check for many years, even though imaging or other studies show the remaining sites of disease. This situation may be referred to as a partial remission.
For patients without symptoms and with indolent subtypes of B-cell NHL, the treatment may be the watch-and-wait approach, meaning treatment is deferred or delayed until signs of disease progression occur. Frequent and careful observation is required so that effective treatment can be started if the disease starts advancing. Some patients have a long-time slow-growing disease, while others have a condition that evolves (transforms) into a more aggressive type of B-cell NHL that requires immediate treatment.
In general, chemotherapy and radiation therapy are the two principal forms of treatment for B-cell NHL. Although radiation therapy is often neither the sole nor the principal curative therapy, it is an important additional treatment in some cases.
The current treatment approaches include Rituximab based mono and combination therapies, Monoclonal antibodies based regimen except Rituximab, Immune Checkpoint inhibitors, Immunomodulators, Proteasome inhibitors, Kinase inhibitors, CAR-T cell therapies, and Histone deacetylase (HDAC) inhibitors.
The following drugs are approved under abovementioned classes, Brukinsa (Zanubrutinib, a product of BeiGene), Polivy (Polatuzumab vedotin, a product of Hoffmann-La Roche), Venetoclax (ABT199, a product of AbbVie and Roche), Kymriah (tisagenlecleucel, a product of Novartis), Yescarta (Axicabtagene ciloleucel, a product of Gilead Sciences), Aliqopa (Copanlisib, a product of Bayer), Imbruvica (Ibrutinib, a product of Janssen/Pharmacyclics (AbbVie Company)), Zydelig (Idelalisib, a product of Gilead Sciences), Gazyva (Obinutuzumab, a product of Genentech, Roche Group), Zevalin (ibritumomab tiuxetan, a product of Spectrum Pharmaceuticals), Velcade (bortezomib, a product of Takeda (Millennium Pharmaceuticals) and Janssen Pharmaceutical), Revlimid (lenalidomide, a product of Celgene Corporation) and others.
B-cell NHL Market Outlook The market size of B-cell NHL in seven major markets (7MM) is estimated to be USD 4,103 million in 2017. The United States accounts for the highest market size of B-cell NHL in comparison to the other major markets i.e., EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan. Among the EU5 countries, Germany had the highest market size in 2017, while Spain had the lowest market size of B-cell NHL in 2017.
B-cell NHL Drugs Uptake
With the launch of emerging therapies like Lisocabtagene maraleucel (JCAR017, a product of Bristol-Myers Squibb), which is an anti-CD-19-directed CAR T-cell product administered intravenously in defined composition at a precise dose of CD8 and CD4 CAR T cells which induced durable responses in poor-prognosis patients with R/R aggressive NHL after at least two prior therapies, KTE-X19 (Gilead Sciences), Tafasitamab (MOR208, a product of MorphoSys AG), Tazemetostat (E7438, a product of Epizyme), Abexinostat (Xynomic Pharmaceuticals), Umbralisib (TG Therapeutics), Avelumab (Pfizer/Merck) and others, the market of B-cell NHL is anticipated to change during the forecast period (2019-2028).
Products that are anticipated to be launched during the forecast period are in late clinical stages of development, while others are in ongoing late clinical development stages. Some of the above-mentioned drug candidates have shown very promising results and it has been anticipated by Analysts that completion of clinical development and launch of these products in the market, might increase the market share of these companies, and besides this, patients of B-cell NHL will have better management practices.
According to our assessment, potential emerging candidates shall launch in the upcoming years of the forecast period [2019-2028], and with their anticipated launch, the market size of B-cell NHL will also experience significant growth.
Key Topics Covered
1. Key Insights
2. Executive Summary of B-cell NHL
3. SWOT Analysis for B-cell NHL
4. B-cell NHL: Patient Share of B-cell NHL at a Glance 4.1. Total Patient Share (%) Distribution in B-cell NHL First-line Therapies in 2017 4.2. Total Patient Share (%) Distribution in B-cell NHL First-line Therapies in 2028 4.3. Total Patient Share (%) Distribution in Relapsed/Refractory B-cell NHL in 2017 4.4. Total Patient Share (%) Distribution in Relapsed/Refractory B-cell NHL in 2028
5. B-cell NHLs: Market Overview at a Glance 5.1. Total Market Share (%) Distribution of B-cell NHL in 2017 5.2. Total Market Share (%) Distribution of B-cell NHL in 2028
6. B-cell Non-Hodgkin Lymphoma (NHL): Disease Background and Overview 6.1. Types of B-cell NHL 6.1.1. Diffuse large B-cell lymphoma (DLBCL) 6.1.2. Burkitt Lymphoma (BL) 6.1.3. Mantle Cell Lymphoma (MCL) 6.1.4. Follicular Lymphoma (FL) 6.1.5. Marginal Zone Lymphoma (MZL) 6.1.6. Chronic Lymphocytic Leukemia (CLL) and Small-Cell Lymphocytic Lymphoma (SLL) 6.2. Origin and Pathogenesis of B-cell NHL 6.2.1. Genetic Lesions in the Pathogenesis of B-cell Lymphomas 6.2.2. Microenvironmental Interactions in B-Cell Lymphomas and the Role of the BCR 6.3. Risk Factors for NHL 6.4. Staging for B-cell NHL 6.4.1. Staging of NHL in Adults 6.4.2. Staging of NHL in Children 6.4.3. Staging Systems for Chronic Lymphocytic Lymphoma (CLL) 6.5. Survival Rate for NHL (5-year) 6.6. Diagnosis of NHL 6.6.1. Diagnostic Algorithm for B-cell NHL 6.6.2. Evaluation 6.6.3. Testing Strategies to Diagnose B-cell Lymphomas 6.6.4. Stratification of High-Grade B-cell Lymphomas Using Laboratory Techniques 6.6.5. Summary of Recommendations for Diagnosis and pathology/molecular biology (DLBCL): European Society for Medical Oncology (ESMO)
7. Epidemiology and Patient Population 7.1. Epidemiology Key Findings 7.2. Assumptions and Rationale: 7MM
8. Epidemiology Scenario: 7MM 8.1. Total Incidence of NHL in the 7MM 8.1.1. Total Incidence cases of B cell-NHL in the 7MM 8.1.2. Gender-specific Incidence of B-cell NHL in the 7MM 8.1.3. Age-specific Incidence of B-cell NHL in the 7MM 8.1.4. Subtype - Specific Incidence of B-cell NHL in the 7MM 8.1.5. Stage-Specific Incidence of B-cell NHL in the 7MM
9. United States Epidemiology 9.1. Total Incidence cases of B cell-NHL in the United States 9.2. Age-specific Incidence of B-cell NHL in the United States 9.3. Subtype-Specific Incidence of B-cell NHL in the United States 9.4. Stage-Specific Incidence of B-cell NHL in the United States
10. EU-5 Country-wise Epidemiology 10.1. Germany Epidemiology 10.1.1. Total Incidence cases of B cell-NHL in Germany 10.1.2. Age-specific Incidence of B-cell NHL in Germany 10.1.3. Subtype-Specific Incidence of B-cell NHL in Germany 10.1.4. Stage-Specific Incidence of B-cell NHL in Germany 10.2. France Epidemiology 10.3. Italy Epidemiology 10.4. Spain Epidemiology 10.5. United Kingdom Epidemiology
11. Japan Epidemiology 11.1. Total Incidence cases of B cell-NHL in Japan 11.2. Age-specific Incidence of B-cell NHL in Japan 11.3. Subtype-Specific Incidence of B-cell NHL in Japan 11.4. Stage-Specific Incidence of B-cell NHL in Japan
12. Current Treatment Practices for B-cell NHL: As per Leukemia & Lymphoma Society (LLS) 12.1. Treatment Overview 12.1.1. Factors That Influence Treatment 12.1.2. The International Prognostic Index (IPI) 12.1.3. Treatment Considerations for Children, Adolescents, and Young Adults 12.2. Treatment of B-cell NHL Subtypes 12.2.1. Diffuse Large B-Cell Lymphoma (DLBCL) 12.2.2. Burkitt Lymphoma 12.2.3. Mantle Cell Lymphoma (MCL) 12.2.4. Follicular Lymphoma (FL) 12.2.5. Marginal Zone Lymphoma (MZL) 12.2.6. Small-Cell Lymphocytic Lymphoma (SLL) and Chronic Lymphocytic Leukemia (CLL)
16. B-cell NHL: Seven Major Market Analysis 16.1. Key Findings 16.2. Total Market Size of B-cell NHL in the 7MM 16.3. Market Size of B-cell NHL by Therapeutic Class in the 7MM
17. Market Outlook: 7MM
18. United States Market Size 18.1. Total Market size of B-cell NHL in the United States 18.2. Market Size of B-cell NHL by Line of Therapies in the US
19. EU-5 Market Size 19.1. Germany Market Size 19.1.1. Total Market size of B-cell NHL in Germany 19.1.2. Market Size of B-cell NHL by Line of Therapies in Germany 19.2. France Market Size 19.3. Italy Market Size 19.4. Spain Market Size 19.5. United Kingdom Market Size
20. Japan Market Size 20.1. Total Market size of B-cell NHL in Japan 20.2. Market Size of B-cell NHL by Therapies in Japan
21. Market Access and Reimbursement Scenario of B-cell NHL Therapies 21.1. CAR-T cell Therapies